Back to top
more

Globus Medical (GMED)

(Delayed Data from NYSE)

$74.88 USD

74.88
686,225

+1.34 (1.82%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $74.90 +0.02 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

CAH Stocks Gains on Q1 Earnings & Sales Beat and Raised '25 EPS View

Cardinal Health's first-quarter fiscal 2025 results benefit from solid Pharmaceutical and Specialty Solutions growth. However, OptumRx contract expiry hurts sales.

Boston Scientific Stock Gains From Market Expansion, Innovation

BSX's Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of gastrointestinal and pulmonary treatment options.

PAHC Stock Likely to Gain From Its Latest Acquisition of Zoetis

Phibro successfully acquires Zoetis Inc.'s MFA portfolio and certain water-soluble products.

Gear Up for Globus Medical (GMED) Q3 Earnings: Wall Street Estimates for Key Metrics

Beyond analysts' top -and-bottom-line estimates for Globus Medical (GMED), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024.

Avanos Q3 Earnings Meet Estimates, Sales Miss, Gross Margin Contracts

Strength in AVNS' Digestive Health segment drives its third-quarter performance

CONMED Beats on Q3 Earnings, Misses on Sales, Lowers '24 Sales View

CNMD's Q3 earnings beat estimates on the back of higher revenues and lower costs and expenses.

GE HealthCare Q3 Earnings Beat Estimates, Sales Meet, Net Margin Up

GEHC's third-quarter results witness declining segmental revenues in imaging and ultrasound, offset by strong Pharmaceutical Diagnostics performance. The bottom line improves on better pricing.

Positive Trial Data on Symplicity RDN System Likely to Support MDT Stock

Medtronic announces new long-term favorable data for its Symplicity Spyral RDN system, which has undergone a SPYRAL HTN-ON MED clinical trial.

Inari Medical Q3 Earnings Miss Estimates, Revenues Increase Y/Y

NARI's third-quarter results witness an increase in revenues with dismal bottom-line performance. Gross margins contract while the company continues to incur operating losses.

TransMedics Stock Falls as Q3 Earnings & Sales Miss Estimates

TMDX's third-quarter revenues increase with the utilization of the OCS across all three organs and additional revenues generated by its logistics services. Gross margin contracts.

ABT's New Trial on Advanced Heart Failure Outcomes Set to Boost Stock

Abbott initiates the TEAM-HF trial to improve outcomes for advanced heart failure.

Is GMED Stock a Smart Addition to Your Portfolio Right Now?

Globus Medical's synergistic merger with NuVasive and a cadence of product launches bring optimism to investors.

TFX Stock to Gain From Launch of New Vascular Access Devices in Canada

Teleflex launches the next-generation Arrow VPS Rhythm DLX Device and NaviCurve Stylet in Canada.

West Pharmaceutical Stock Gains on Q3 Earnings Beat & Raised Guidance

WST's third-quarter results reflect a recovery in the Proprietary Products segment following elevated customer destocking, hurting sales in the second quarter.

BSX Q3 Earnings Top, Stock Down in Premarket as Operating Margin Falls

Boston Scientific registers year-over-year improvement in sales, indicating solid market share gains in legacy businesses despite macroeconomic odds.

Intuitive Surgical Q3 Earnings Beat, Procedures Robust

ISRG's third-quarter results reflect a healthy demand for procedures. Higher pricing boosts procedure sales. An improvement in margins buoys well.

Globus Medical Expands Orthopedic Trauma Portfolio With New Launches

GMED launches ANTHEM II Distal Radius Volar Plates, AUTOBAHN Trochanteric Nail PRO Instruments and CAPTIVATE SOLA Headless Screws.

GMED or SONVY: Which Is the Better Value Stock Right Now?

GMED vs. SONVY: Which Stock Is the Better Value Option?

Why Is Globus Medical (GMED) Down 0.2% Since Last Earnings Report?

Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is It Apt to Hold Globus Medical Stock in Your Portfolio Now?

GMED's robust prospects in the musculoskeletal field and the synergies from the NuVasive merger bode well. Yet, macroeconomic issues can affect performance.

Globus Medical's (GMED) Lateral Interbody Portfolio Gets New Launch

Globus Medical's (GMED) lateral interbody portfolio gets its first commercial product launch with ADIRA XLIF Plate System.

Zimmer Biomet's (ZBH) Latest Deal to Expand Its Hip Portfolio

Zimmer Biomet (ZBH) announces the acquisition of OrthoGrid to expand its hip portfolio with an AI-driven surgical guidance system.

Here's Why Globus Medical (GMED) is a Strong Momentum Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why Globus Medical (GMED) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Globus Medical (GMED) Q2 Earnings Top Estimates, '24 View Up

Globus Medical (GMED) delivers massive sales and earnings growth in the second quarter of 2024. However, margins contract.